Over the past decade, medical therapy for RCC has shifted from non-specific immune approaches (in the era of cytokines) to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents [3, 4]. Here, VEGFA is linked to renal cell carcinoma.